# MBX Biosciences, Inc.: financial statements, quarterly

MBX · Nasdaq · CIK 1776111 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mbx.md) · [Financials](/companies/mbx/financials.md) · [Filings](/companies/mbx/filings.md) · [Insiders](/companies/mbx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mbx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [9.1](/filings/0000950170-24-122840.md) | [7.7 d](/filings/0000950170-25-039838.md) | [11.0](/filings/0000950170-25-068602.md) | [14.4](/filings/0000950170-25-104619.md) | [16.7](/filings/0001193125-25-268148.md) | [15.2 d](/filings/0001193125-26-103121.md) | [22.4](/filings/0001193125-26-210593.md) | [17.7](/filings/0001193125-26-336849.md) | [19.3](/filings/0001193125-25-268148.md) | [19.8 d](/filings/0001193125-26-103121.md) | [18.5](/filings/0001193125-26-210593.md) | [31.0](/filings/0001193125-26-336849.md) |
| Operating income | $m | [(10.9)](/filings/0000950170-24-122840.md) | [(10.0) d](/filings/0000950170-25-039838.md) | [(13.3)](/filings/0000950170-25-068602.md) | [(16.7)](/filings/0000950170-25-104619.md) | [(19.6)](/filings/0001193125-25-268148.md) | [(18.6) d](/filings/0001193125-26-103121.md) | [(26.5)](/filings/0001193125-26-210593.md) | [(21.8)](/filings/0001193125-26-336849.md) | [(23.9)](/filings/0001193125-25-268148.md) | [(25.8) d](/filings/0001193125-26-103121.md) | [(27.3)](/filings/0001193125-26-210593.md) | [(40.9)](/filings/0001193125-26-336849.md) |
| Net income | $m | [(10.2)](/filings/0000950170-24-122840.md) | [(8.8) d](/filings/0000950170-25-039838.md) | [(12.3)](/filings/0001193125-25-268148.md) | [(15.9)](/filings/0001193125-25-268148.md) | [(18.1)](/filings/0001193125-25-268148.md) | [(15.6) d](/filings/0001193125-26-103121.md) | [(23.9)](/filings/0001193125-26-336849.md) | [(19.4)](/filings/0001193125-26-336849.md) | [(21.6)](/filings/0001193125-25-268148.md) | [(22.1) d](/filings/0001193125-26-336849.md) | [(23.5)](/filings/0001193125-26-336849.md) | [(37.1)](/filings/0001193125-26-336849.md) |
| Diluted EPS | $ per share | [(9.40)](/filings/0000950170-24-122840.md) | not reported | [(10.26)](/filings/0000950170-25-068602.md) | [(12.62)](/filings/0000950170-25-104619.md) | [(2.78)](/filings/0001193125-25-268148.md) | not reported | [(0.71)](/filings/0001193125-26-210593.md) | [(0.58)](/filings/0001193125-26-336849.md) | [(0.63)](/filings/0001193125-25-268148.md) | not reported | [(0.50)](/filings/0001193125-26-210593.md) | [(0.78)](/filings/0001193125-26-336849.md) |
| Basic EPS | $ per share | [(9.40)](/filings/0000950170-24-122840.md) | not reported | [(10.26)](/filings/0000950170-25-068602.md) | [(12.62)](/filings/0000950170-25-104619.md) | [(2.78)](/filings/0001193125-25-268148.md) | not reported | [(0.71)](/filings/0001193125-26-210593.md) | [(0.58)](/filings/0001193125-26-336849.md) | [(0.63)](/filings/0001193125-25-268148.md) | not reported | [(0.50)](/filings/0001193125-26-210593.md) | [(0.78)](/filings/0001193125-26-336849.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [30.5](/filings/0000950170-25-039838.md) | not reported | not reported | [133](/filings/0000950170-24-122840.md) | [49.4](/filings/0001193125-26-103121.md) | [29.9](/filings/0000950170-25-068602.md) | [39.8](/filings/0000950170-25-104619.md) | [223](/filings/0001193125-25-268148.md) | [75.3](/filings/0001193125-26-336849.md) | [45.2](/filings/0001193125-26-210593.md) | [54.1](/filings/0001193125-26-336849.md) |
| Current assets | $m | not reported | [83.5](/filings/0000950170-25-039838.md) | not reported | not reported | [281](/filings/0000950170-24-122840.md) | [267](/filings/0001193125-26-103121.md) | [244](/filings/0000950170-25-068602.md) | [229](/filings/0000950170-25-104619.md) | [398](/filings/0001193125-25-268148.md) | [382](/filings/0001193125-26-336849.md) | [449](/filings/0001193125-26-210593.md) | [428](/filings/0001193125-26-336849.md) |
| Total assets | $m | not reported | [84.2](/filings/0000950170-25-039838.md) | not reported | not reported | [282](/filings/0000950170-24-122840.md) | [269](/filings/0001193125-26-103121.md) | [246](/filings/0000950170-25-068602.md) | [232](/filings/0000950170-25-104619.md) | [400](/filings/0001193125-25-268148.md) | [385](/filings/0001193125-26-336849.md) | [453](/filings/0001193125-26-210593.md) | [436](/filings/0001193125-26-336849.md) |
| Current liabilities | $m | not reported | [3.9](/filings/0000950170-25-039838.md) | not reported | not reported | [10.9](/filings/0000950170-24-122840.md) | [11.1](/filings/0001193125-26-103121.md) | [10.5](/filings/0000950170-25-068602.md) | [11.8](/filings/0000950170-25-104619.md) | [12.1](/filings/0001193125-25-268148.md) | [15.5](/filings/0001193125-26-336849.md) | [14.6](/filings/0001193125-26-210593.md) | [23.7](/filings/0001193125-26-336849.md) |
| Total liabilities | $m | not reported | [4.3](/filings/0000950170-25-039838.md) | not reported | not reported | [11.0](/filings/0000950170-24-122840.md) | [11.1](/filings/0001193125-26-103121.md) | [10.5](/filings/0000950170-25-068602.md) | [12.3](/filings/0000950170-25-104619.md) | [12.5](/filings/0001193125-25-268148.md) | [15.9](/filings/0001193125-26-336849.md) | [14.9](/filings/0001193125-26-210593.md) | [26.4](/filings/0001193125-26-336849.md) |
| Shareholders' equity | $m | [(64.8)](/filings/0000950170-24-122840.md) | [(72.5)](/filings/0001193125-26-103121.md) | [(83.0)](/filings/0001193125-25-268148.md) | [(97.9)](/filings/0001193125-25-268148.md) | [271](/filings/0001193125-25-268148.md) | [257](/filings/0001193125-26-336849.md) | [235](/filings/0001193125-26-336849.md) | [219](/filings/0001193125-26-336849.md) | [388](/filings/0001193125-25-268148.md) | [369](/filings/0001193125-26-336849.md) | [438](/filings/0001193125-26-336849.md) | [410](/filings/0001193125-26-336849.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.1) d](/filings/0000950170-25-039838.md) | [(10.7)](/filings/0000950170-25-068602.md) | [(13.3) d](/filings/0000950170-25-104619.md) | [(14.7) d](/filings/0001193125-25-268148.md) | [(16.0) d](/filings/0001193125-26-103121.md) | [(22.7)](/filings/0001193125-26-210593.md) | [(17.4) d](/filings/0001193125-26-336849.md) | [(21.5) d](/filings/0001193125-25-268148.md) | [(18.3) d](/filings/0001193125-26-103121.md) | [(20.2)](/filings/0001193125-26-210593.md) | [(22.6) d](/filings/0001193125-26-336849.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-25-039838.md) | [0.3](/filings/0000950170-25-068602.md) | [0.5 d](/filings/0000950170-25-104619.md) | [0.1 d](/filings/0001193125-25-268148.md) | [0.1 d](/filings/0001193125-26-103121.md) | [0.0](/filings/0001193125-26-210593.md) | [0.7 d](/filings/0001193125-26-336849.md) | [0.4 d](/filings/0001193125-25-268148.md) | [0.8 d](/filings/0001193125-26-103121.md) | [0.4](/filings/0001193125-26-210593.md) | [0.9 d](/filings/0001193125-26-336849.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.1](/filings/0000950170-24-122840.md) | [1.2](/filings/0000950170-25-068602.md) | [1.3](/filings/0000950170-25-104619.md) | [6.5](/filings/0001193125-25-268148.md) | [33.4](/filings/0001193125-26-210593.md) | [33.4](/filings/0001193125-26-336849.md) | [34.2](/filings/0001193125-25-268148.md) | [46.6](/filings/0001193125-26-210593.md) | [47.7](/filings/0001193125-26-336849.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,160,096 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336849.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.